Eledon Pharmaceuticals, Inc.
ELDN
$2.82
-$0.11-3.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -182.01% | -500.85% | 76.59% | -122.68% | 75.02% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 226.25% | 366.09% | -130.99% | 101.77% | -129.30% |
| Change in Net Operating Assets | -204.54% | -149.52% | 407.05% | -81.03% | 9.40% |
| Cash from Operations | -28.02% | -40.80% | 25.79% | -23.01% | -127.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 55.35% | 53.03% | 56.81% | 196.90% | 175.12% |
| Cash from Investing | 55.35% | 53.03% | 56.81% | 196.90% | 175.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -33.02% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -33.02% | -100.00% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 123.63% | -38.19% | 38.71% | 89.26% | -113.52% |